Download Image
    
Share
  
Post
c19early.org
Losartan for COVID-19
7 studies with >1,000 patients
Serious outcome risk
Losartan
Control
No significant improvements are seen in meta-analysis to date.
COVID-19 Losartan studies · October 2026
Recent:
Simeone.
Covid Analysis Losartan for COVID-19: real-time meta-analysis of 7 studies (Version 4)
Meta-analysis using the most serious outcome reported shows 5% [-32‑62%] higher risk, without reaching statistical significance. Currently all studies are RCTs. Currently there is limited data, with only 37 control events for t..
Sep 25
 Simeone et al., Respiratory Medicine, doi:10.1016/j.rmed.2026.109175 Losartan with add-on spironolactone for severe COVID-19 in the intensive care unit: a randomized controlled trial
37% lower mortality (p=0.45), 27% lower ventilation (p=0.3), 37% lower need for oxygen therapy (p=0.3), and 33% improvement (p=0.5). RCT 74 ICU patients (modified intention-to-treat) showing no significant differences with losartan plus conditional add-on spironolactone for severe COVID-19 ARDS.
Jul 10
2024
 Tran et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae306 Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial
14% higher mortality (p=0.69), 1% higher ventilation (p=0.96), 3% higher need for oxygen therapy (p=0.43), and 75% higher ICU admission (p=0.21). RCT 341 hospitalized COVID-19 patients showing significant harm with losartan treatment. The trial was stopped early due to safety concerns after losartan patients experienced significantly higher rates of serious adverse events (39.8% vs..
Dec 31
2022
 Götberg et al., SSRN Electronic Journal, doi:10.2139/ssrn.4278529 Effect of Adding Losartan to Standard of Care Treatment on the Risk of Death and Icu Admission Among Hospitalized COVID-19 Patients: A Randomized Trial
77% lower ventilation (p=0.01) and 36% lower ICU admission (p=0.24). RCT 302 hospitalized COVID-19 patients showing lower mechanical ventilation but no significant difference in ICU admission or mortality with losartan treatment.
Oct 31
2022
 Freilich et al., Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2022.100968 COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients
533% higher mortality (p=0.49) and 160% longer hospitalization (p=0.3). RCT 15 hospitalized COVID-19 patients showing no significant differences with losartan treatment. The study was terminated early due to low enrollment.
Mar 19
2022
 Mirjalili et al., BMC Cardiovascular Disorders, doi:10.1186/s12872-022-02548-2 Does Losartan reduce the severity of COVID-19 in hypertensive patients?
81% lower mortality (p=0.003) and 3% fewer cases (p=0.86). Retrospective study of 280 hypertensive patients in Iran showing lower mortality with losartan use in COVID-19 patients, however data is contradictory and unclear. The text and Figure 1 indicate that 179 of 280 patients were PCR+, however..
Mar 16
2022
 Puskarich et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.2735 Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
3% higher mortality (p=1), 27% higher ventilation (p=0.47), and 3% lower need for oxygen therapy (p=0.66). RCT 205 hospitalized COVID-19 patients showing no significant difference in lung injury (PaO2:FiO2 ratio) at day 7 with losartan treatment, and no difference in clinical outcomes including mortality. Losartan was associated with more adve..
Jul 31
2021
 Puskarich et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.100957 A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
2% higher ICU admission (p=1), 205% higher hospitalization (p=0.36), and 27% higher progression (p=0.74). RCT 117 symptomatic outpatients showing no significant difference in hospitalization, functional status, dyspnea, or viral load with losartan treatment. The trial was terminated early due to low event rates. Losartan 25mg twice daily for ..
May 11
2021
 Geriak et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00453-3 Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
6% lower mortality (p=1), 53% lower ICU admission (p=0.6), 53% higher hospital discharge (p=0.6), and 10% shorter hospitalization. RCT 31 hospitalized COVID-19 patients with mild hypoxemia showing no significant difference in mechanical ventilation, ICU admission, or mortality with addition of losartan to standard care.